Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Alberta

$17,500.00

Evaluation of Human Endogenous Retrovirus Proteins as Cancer Biomarkers using Immunoaffinity-Mass Spectrometry

EF 2020-21

Résumé
Millions of years ago, viruses infected and integrated into our germline genome and have been passed down. These viruses are known as Human Endogenous Retroviruses (HERVs) and currently there are limited studies to assess whether these genes encode for proteins and to study their function. There has been an interest in assessing the potential role of a specific group of HERVs, called HERV-K envelope (env) proteins in cancer development. As such, I hypothesize that HERV-K env proteins are a promising class of cancer biomarkers that can be detected and quantified using a highly sensitive and specific tool called immunoaffinity-mass spectrometry (IA-MS) assays. Different HERV-K env proteins have very similar protein sequences which hinders commonly used tools such as immunoassays from being able to differentiate between them. IA-MS takes the best of two worlds by using immunoassays' high sensitivity which uses specific antibodies to capture only our proteins of interest from the entire sample. Following this, our concentrated sample with our proteins of interest will be analyzed by mass spectrometry where its high level of specificity can tell us each individual amino acid (building block) of the captured proteins. Notably, due to our lab's expertise, resources, and collaborations, I will first assess HERV-K env protein expression in prostate cancer cell lines. Concurrently, I will develop IA-MS assays to detect and quantify these proteins. Lastly, I will evaluate the expression of these proteins in clinical samples (prostate tissue biopsies, seminal plasma, and blood serum). The successful implementation of this project will further our knowledge on a fairly unstudied area of the human genome and aid in finding novel biomarkers for prostate cancer diagnosis.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
449460
Name
Dara Delaram
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Evaluation of Human Endogenous Retrovirus Proteins as Cancer Biomarkers using Immunoaffinity-Mass Spectrometry
Programtype2
Studentship Programs
Orgnameinp2
University of Alberta
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Biomarker; Cancer Detection; Cancer Diagnostics; Human Endogenous Retrovirus-Group K Envelope Proteins; Immunoaffinity-Mass Spectrometry; Mass Spectrometry; Prostate Cancer; Quantitative Proteomics
Abstract
Millions of years ago, viruses infected and integrated into our germline genome and have been passed down. These viruses are known as Human Endogenous Retroviruses (HERVs) and currently there are limited studies to assess whether these genes encode for proteins and to study their function. There has been an interest in assessing the potential role of a specific group of HERVs, called HERV-K envelope (env) proteins in cancer development. As such, I hypothesize that HERV-K env proteins are a promising class of cancer biomarkers that can be detected and quantified using a highly sensitive and specific tool called immunoaffinity-mass spectrometry (IA-MS) assays. Different HERV-K env proteins have very similar protein sequences which hinders commonly used tools such as immunoassays from being able to differentiate between them. IA-MS takes the best of two worlds by using immunoassays' high sensitivity which uses specific antibodies to capture only our proteins of interest from the entire sample. Following this, our concentrated sample with our proteins of interest will be analyzed by mass spectrometry where its high level of specificity can tell us each individual amino acid (building block) of the captured proteins. Notably, due to our lab's expertise, resources, and collaborations, I will first assess HERV-K env protein expression in prostate cancer cell lines. Concurrently, I will develop IA-MS assays to detect and quantify these proteins. Lastly, I will evaluate the expression of these proteins in clinical samples (prostate tissue biopsies, seminal plasma, and blood serum). The successful implementation of this project will further our knowledge on a fairly unstudied area of the human genome and aid in finding novel biomarkers for prostate cancer diagnosis.
Competitiondate
202012
Approvedterm2
1 yr 0 mth
Pinamesdelim
Dara, Delaram
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~